Venture Capital Flowing Into Kendall Square Biotech Corridor Hits New High

Venture capital investment in the Kendall Square biotech corridor, often described as the most concentrated square mile of biotech research in the world, reached its highest level in five years last quarter, according to data compiled by a regional life sciences trade group, driven largely by continued investor interest in cell and gene therapy startups.

The corridor, anchored by MIT and a dense cluster of pharmaceutical company research campuses, has developed one of the country's most established concentrations of biotech companies spun out of university research, and investment data shows funding increasingly concentrated in later-stage companies moving therapies toward clinical trials rather than earliest-stage seed deals.

"What's different about Kendall Square compared with other biotech hubs is how much of the early science traces directly back to MIT and Harvard labs within walking distance of each other," said the trade group's chief economist, who compiled the funding report. "Investors have recognized that density as a genuine competitive advantage for a long time now."

The report found that Massachusetts-based biotech companies raised significantly more in later-stage funding rounds compared with the prior year, even as overall national venture funding for early-stage biotech deals remained relatively flat. Several Kendall Square companies completed funding rounds exceeding $150 million during the period.

State economic development officials have pointed to the funding data as validation of continued public investment in biotech incentives, including tax credits for life sciences companies that locate or expand within the state. Industry representatives said the corridor's continued growth will depend partly on whether Massachusetts can keep pace with laboratory space construction to accommodate expanding companies.